1. Home
  2. SKYH vs MIST Comparison

SKYH vs MIST Comparison

Compare SKYH & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYH
  • MIST
  • Stock Information
  • Founded
  • SKYH 2017
  • MIST 2003
  • Country
  • SKYH United States
  • MIST Canada
  • Employees
  • SKYH N/A
  • MIST N/A
  • Industry
  • SKYH Military/Government/Technical
  • MIST Biotechnology: Pharmaceutical Preparations
  • Sector
  • SKYH Industrials
  • MIST Health Care
  • Exchange
  • SKYH Nasdaq
  • MIST Nasdaq
  • Market Cap
  • SKYH N/A
  • MIST 53.9M
  • IPO Year
  • SKYH N/A
  • MIST N/A
  • Fundamental
  • Price
  • SKYH $11.65
  • MIST $1.11
  • Analyst Decision
  • SKYH Strong Buy
  • MIST Strong Buy
  • Analyst Count
  • SKYH 2
  • MIST 2
  • Target Price
  • SKYH $15.25
  • MIST $9.50
  • AVG Volume (30 Days)
  • SKYH 101.3K
  • MIST 1.6M
  • Earning Date
  • SKYH 05-13-2025
  • MIST 05-20-2025
  • Dividend Yield
  • SKYH N/A
  • MIST N/A
  • EPS Growth
  • SKYH N/A
  • MIST N/A
  • EPS
  • SKYH N/A
  • MIST N/A
  • Revenue
  • SKYH $14,761,000.00
  • MIST N/A
  • Revenue This Year
  • SKYH $122.85
  • MIST N/A
  • Revenue Next Year
  • SKYH $61.16
  • MIST N/A
  • P/E Ratio
  • SKYH N/A
  • MIST N/A
  • Revenue Growth
  • SKYH 94.86
  • MIST N/A
  • 52 Week Low
  • SKYH $8.26
  • MIST $0.63
  • 52 Week High
  • SKYH $14.52
  • MIST $2.75
  • Technical
  • Relative Strength Index (RSI)
  • SKYH 56.09
  • MIST 43.96
  • Support Level
  • SKYH $10.88
  • MIST $1.28
  • Resistance Level
  • SKYH $11.43
  • MIST $1.32
  • Average True Range (ATR)
  • SKYH 0.41
  • MIST 0.12
  • MACD
  • SKYH 0.07
  • MIST 0.02
  • Stochastic Oscillator
  • SKYH 57.69
  • MIST 27.39

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Share on Social Networks: